嶺東科技大學 |

[NT 42591] Language: 簡体中文

[NT 5635] Back

[NT 59884] Switch To: [NT 5556] Labeled | [NT 5559] MARC Mode | [NT 33762] ISBD

Incentives for global public health : patent law and access to essential medicines

[NT 42944] Record Type:	[NT 1579] Language materials, printed : [NT 40817] monographic
[NT 47348] Title Information:	patent law and access to essential medicines
[NT 47354] Secondary Intellectual Responsibility:	RubensteinKim,
[NT 47354] Secondary Intellectual Responsibility:	RimmerMatthew,
[NT 47354] Secondary Intellectual Responsibility:	PoggeThomas Winfried Menko,
[NT 47351] Place of Publication:	Cambridge, UK
[NT 47263] Published:	Cambridge University Press;
[NT 47352] Year of Publication:	2010
[NT 47264] Description:	xxi, 512 p.24 cm.;
[NT 47298] Series:	Connecting international law with public law
[NT 47266] Subject:	Pharmaceutical policy. -
[NT 47266] Subject:	Patents (International law) -
[NT 47266] Subject:	Patent laws and legislation. -
[NT 47266] Subject:	Drugs - Patents. -
[NT 51398] Summary:	"This portrait of the global debate over patent law and access to essential medicines focuses on public health concerns about HIV/AIDS, malaria, tuberculosis, the SARS virus, influenza, and diseases of poverty. The essays explore the diplomatic negotiations and disputes in key international fora, such as the World Trade Organization, the World Health Organization and the World Intellectual Property Organization. Drawing upon international trade law, innovation policy, intellectual property law, health law, human rights and philosophy, the authors seek to canvass policy solutions which encourage and reward worthwhile pharmaceutical innovation while ensuring affordable access to advanced medicines. A number of creative policy options are critically assessed, including the development of a Health Impact Fund, prizes for medical innovation, the use of patent pools, open-source drug development and forms of 'creative capitalism'"--Provided by publisher
[NT 50961] ISBN:	978-0-521-11656-5bound
[NT 50961] ISBN:	0-521-11656-2bound
[NT 60779] Content Note:	Introduction: access to essential medicines: public health and international law / Thomas Pogge, Matthew Rimmer and Kim Rubenstein --TRIPS and essential medicines: must one size fit all? Making the WTO responsive to the global health crisis / Rochelle C. Dreyfuss --The TRIPS waiver as a recognition of public health concerns in the WTO / Andrew D. Mitchell and Tania Voon Public law challenges to the regulation of pharmaceutical patents in the US bilateral free trade agreements / Hitoshi Nasu Global health and development: patents and public interest / Elizabeth Siew Kuan Ng --The Health Impact Fund: better pharmaceutical innovations at much lower price / Thomas Pogge The Health Impact Fund: a critique / Kathleen Liddell A prize system as a partial solution to the health crisis in the developing world / William W. Fisher and Talha Syed Innovation and insufficient evidence: the case for a WTO-WHO agreement on health technology safety and cost-effectiveness evaluation / Thomas Faunce Opening the dam: patent pools, innovation, and access to essential medicines / Dianne Nicol and Jane Nielsen Open source drug discovery: a revolutionary paradigm or a Utopian model? Krishna Ravi Srinivas Accessing and benefit sharing avian influenza viruses through the World Health Organisation: a CBD and TRIPS compromise thanks to Indonesia's sovereignty claim? / Charles Lawson and Barbara Ann Hocking The Lazarus effect: the (RED) campaign and creative capitalism / Matthew Rimmer Beyond TRIPS: the role of non-state actors and access to essential medicines / Noah Benjamin Novogrodsky Securing health through rights / Katharine G. Young The role of national laws in reconciling constitutional right to health with TRIPS obligations: an examination of the Glivec patent case in India / Rajshree Chandra Tipping point: Thai compulsory licenses redefine essential medicines debate / Jonathan Burton-MacLeod

Incentives for global public health : patent law and access to essential medicines
Incentives for global public health : patent law and access to essential medicines / edited by Thomas Pogge, Matthew Rimmer, and Kim Rubenstein - Cambridge, UK : Cambridge University Press, 2010. - xxi, 512 p. ; 24 cm.. - (Connecting international law with public law).
Introduction: access to essential medicines: public health and international law / Thomas Pogge, Matthew Rimmer and Kim Rubenstein --TRIPS and essential medicines: must one size fit all? Making the WTO responsive to the global health crisis / Rochelle C. Dreyfuss --The TRIPS waiver as a recognition of public health concerns in the WTO / Andrew D. Mitchell and Tania Voon.
Includes bibliographical references and index..
ISBN 978-0-521-11656-5ISBN 0-521-11656-2
Pharmaceutical policy.Patents (International law)Patent laws and legislation.Drugs - Patents.

Rubenstein, Kim

Incentives for global public health : patent law and access to essential medicines
LDR:03616nam0 2200217 450 001 259892
005 20101206145340.0
010 1 $a 978-0-521-11656-5 $b bound $d NT$3238
010 1 $a 0-521-11656-2 $b bound $d NT$3238
100 $a 20120105d2010 m y0engy01 b
101 0 $a eng
102 $a gb
105 $a y a 001zy
200 1 $a Incentives for global public health $e patent law and access to essential medicines $f edited by Thomas Pogge, Matthew Rimmer, and Kim Rubenstein
210 $a Cambridge, UK $d 2010 $c Cambridge University Press
215 1 $a xxi, 512 p. $d 24 cm.
225 1 # $a Connecting international law with public law
320 $a Includes bibliographical references and index.
327 1 $a Introduction: access to essential medicines: public health and international law / Thomas Pogge, Matthew Rimmer and Kim Rubenstein --TRIPS and essential medicines: must one size fit all? Making the WTO responsive to the global health crisis / Rochelle C. Dreyfuss --The TRIPS waiver as a recognition of public health concerns in the WTO / Andrew D. Mitchell and Tania Voon $a Public law challenges to the regulation of pharmaceutical patents in the US bilateral free trade agreements / Hitoshi Nasu $a Global health and development: patents and public interest / Elizabeth Siew Kuan Ng --The Health Impact Fund: better pharmaceutical innovations at much lower price / Thomas Pogge $a The Health Impact Fund: a critique / Kathleen Liddell $a A prize system as a partial solution to the health crisis in the developing world / William W. Fisher and Talha Syed $a Innovation and insufficient evidence: the case for a WTO-WHO agreement on health technology safety and cost-effectiveness evaluation / Thomas Faunce $a Opening the dam: patent pools, innovation, and access to essential medicines / Dianne Nicol and Jane Nielsen $a Open source drug discovery: a revolutionary paradigm or a Utopian model? Krishna Ravi Srinivas $a Accessing and benefit sharing avian influenza viruses through the World Health Organisation: a CBD and TRIPS compromise thanks to Indonesia's sovereignty claim? / Charles Lawson and Barbara Ann Hocking $a The Lazarus effect: the (RED) campaign and creative capitalism / Matthew Rimmer $a Beyond TRIPS: the role of non-state actors and access to essential medicines / Noah Benjamin Novogrodsky $a Securing health through rights / Katharine G. Young $a The role of national laws in reconciling constitutional right to health with TRIPS obligations: an examination of the Glivec patent case in India / Rajshree Chandra $a Tipping point: Thai compulsory licenses redefine essential medicines debate / Jonathan Burton-MacLeod
330 $a "This portrait of the global debate over patent law and access to essential medicines focuses on public health concerns about HIV/AIDS, malaria, tuberculosis, the SARS virus, influenza, and diseases of poverty. The essays explore the diplomatic negotiations and disputes in key international fora, such as the World Trade Organization, the World Health Organization and the World Intellectual Property Organization. Drawing upon international trade law, innovation policy, intellectual property law, health law, human rights and philosophy, the authors seek to canvass policy solutions which encourage and reward worthwhile pharmaceutical innovation while ensuring affordable access to advanced medicines. A number of creative policy options are critically assessed, including the development of a Health Impact Fund, prizes for medical innovation, the use of patent pools, open-source drug development and forms of 'creative capitalism'"--Provided by publisher
606 # $a Pharmaceutical policy. $2 lc $3 276054
606 # $a Patents (International law) $2 lc $3 268226
606 # $a Patent laws and legislation. $3 122274
606 # $a Drugs - Patents. $2 lc $3 276055
676 $a 362.1782
702 1 $a Rubenstein $b Kim $4 edited $3 271459
702 1 $a Rimmer $b Matthew $4 edited $3 271458
702 1 $a Pogge $b Thomas Winfried Menko $4 edited $3 271457
801 0 $a cw $b 嶺東科技大學圖書館 $g CCR